Bi-weekly: Thursdays, 11 am EDT/EST, 8 am PT/PST, 4 pm BST/BDT, 5 pm CEST/CET
Some seminars were recorded and accessible for a limited time on our youtube channel.
March 7th, 2024
Host: Hojong Yoon
Any target, every time: how proximity-based therapeutics has redefined druggablility
Ryan Potts obtained his Ph.D. in Cell and Molecular Biology from UT Southwestern in 2007. In 2008 he was awarded the Sara and Frank McKnight junior faculty position at UT Southwestern Medical Center and appointed as Assistant Professor in the Departments of Physiology, Pharmacology, and Biochemistry in 2011. In 2016 his lab moved to St. Jude Children’s Research Hospital where he was an Associate Member in the Department of Cell and Molecular Biology. In 2020, he moved to Amgen as Executive Director of Research and Head of the Induced Proximity Platform that is focused on empowering multi-specific, induced proximity therapeutic modalities through bold, creative science to expand the druggable genome and reimaging the future of drug discovery. In 2021, he took over leadership of Amgen’s Postdoctoral Fellows Program aimed at training the next generation of industry scientists. In recognition to his important contributions at Amgen, he was promoted to Scientific Vice President in 2023.
March 21st, 2024
Host: Katherine Donovan & Mikolaj Slabicki
Continuous evolution of compact protein degradation tags regulated by selective cereblon molecular glues
Stephan DeCarlo is a graduate student in Prof. David R. Liu’s lab at the Broad Institute. Stephan received his bachelor’s degree from Bowdoin College and worked on antibody discovery and strain engineering at Adimab prior to attending Harvard. Stephan’s research interests include using phage-assisted continuous evolution (PACE) to engineer proteins with novel functionalities.
Shourya S. Roy Burman
Shourya S. Roy Burman is a Research Fellow in Prof. Eric Fischer’s group at Dana-Farber Cancer Institute and Harvard Medical School. He works on developing new chemically inducible degradation tags using computational methods and characterizing them using structural and biophysical techniques. He received the Cancer Research Institute Irving Postdoctoral Fellowship for exploring the regulation of engineered cell therapies with degron tags. Previously, he completed his Ph.D. at the Johns Hopkins University in Dr. Jeffrey Gray’s group where he developed protein docking programs for the Rosetta Macromolecular Modeling Suite.
Monte Rosa Therapeutics
Teaching CRBN new tricks
Georg Petzold received his PhD in 2012 studying E3 ligase biology and cell cycle regulation under the supervision of Jan-Michael Peters at the Research Institute of Molecular Pathology in Vienna, Austria. In 2014, he joined the lab of Nicolas H. Thomä at the FMI in Basel to elucidate the mode of action of thalidomide analogs, clinical compounds that redirect the CRL4-CRBN E3 ligase to induce target protein degradation in the treatment of multiple myeloma and myelodysplastic syndrome. In 2021, Georg joined the team at Monte Rosa Therapeutics to unleash the full potential of this novel modality, and to develop innovative new medicines that overcome limitations of conventional approaches.
April 4th, 2024
Host: Hojong Yoon
Chemical Facsimile of E3 Cancer Mutations Promotes Corepressor Degradation
Brian Liau is an associate professor in the Department of Chemistry and Chemical Biology at Harvard University. He obtained his bachelor’s degree in Chemistry and Physics from Harvard College, before receiving a PhD in Chemistry under the guidance of Dr. Matthew Shair. During his PhD studies, Brian completed the chemical synthesis of complex bioactive natural products and investigated their biological mechanism of action. As a postdoctoral fellow with Dr. Bradley Bernstein, he studied epigenetic mechanisms of adaptation and drug resistance in brain cancer. In 2016, Brian started his independent research group, which integrates chemical biology with genomics to unravel chromatin complexes and gene regulation. The Liau lab has pioneered chemical genomic approaches to systematically identify drug resistance-conferring mutations for protein drug targets, which they leverage in mechanistic studies to interrogate small molecule mechanism of action and target biology.